Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 821% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 0.3% — below-average profitability
BRUKER CORPORATION (BRKR) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $5.4 billion . Key value metrics: P/E ratio 862.4, P/B ratio 2.21, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BRUKER CORPORATION — Fundamental Analysis Summary
BRUKER CORPORATION (BRKR) is currently trading 821% above its Graham Number of $3.89, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 862.4x.
On financial health, BRKR shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 0.3% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.76.
StockPik's composite Value Score for BRKR is 60/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BRKR reports a solid gross margin of 46.6% (sector average: 33.5%) and a modest operating margin of 1.8%.
BRKR shows revenue growing at 2% year-over-year, with earnings declining at 108%.
BRKR pays a modest dividend yield of 0.6%.